

# Onyee Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556366/publications.pdf>

Version: 2024-02-01

63  
papers

725  
citations

840776

11  
h-index

580821

25  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. <i>Leukemia</i> , 2022, 36, 1189-1192.	7.2	5
2	Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e467-e476.	0.4	5
3	Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
4	Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e52-e56.	0.4	1
5	PTPN11 mutations are associated with poor outcomes across myeloid malignancies. <i>Leukemia</i> , 2021, 35, 286-288.	7.2	11
6	Genomic characteristics and prognostic significance of co-mutated <i>ASXL1</i> and <i>SRSF2</i> acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 462-470.	4.1	19
7	Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. <i>Blood Advances</i> , 2021, 5, 1017-1028.	5.2	41
8	Chronic myelomonocytic leukemia diagnosis and management. <i>Leukemia</i> , 2021, 35, 1552-1562.	7.2	18
9	Luspatercept in the treatment of lower-risk myelodysplastic syndromes. <i>Future Oncology</i> , 2021, 17, 1473-1481.	2.4	3
10	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 2739-2751.	7.2	10
11	Validation of the international working group proposal for <i>SF3B1</i> mutant myelodysplastic syndromes. <i>Blood</i> , 2021, 138, 989-992.	1.4	7
12	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 6095-6105.	7.0	14
13	MYC Overexpression is Associated with an Early Disease Progression from MDS to AML. <i>Leukemia Research</i> , 2021, 111, 106733.	0.8	6
14	High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients. <i>Blood</i> , 2021, 138, 2377-2377.	1.4	0
15	Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 217-217.	1.4	3
16	Outcomes of Patients Treated with CPX-351 As First Line Therapy for AML Based on Their Antecedent History of Myeloid Malignancy. <i>Blood</i> , 2021, 138, 1251-1251.	1.4	1
17	Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML. <i>Blood</i> , 2021, 138, 686-686.	1.4	3
18	Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience. <i>Blood</i> , 2021, 138, 3612-3612.	1.4	1

#	ARTICLE	IF	CITATIONS
19	<i>IDH</i> Mutations Are Enriched in Myelodysplastic Syndromes Patients with Severe Neutropenia: A Potential Targeted Therapy. Blood, 2021, 138, 1526-1526.	1.4	3
20	A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes. Blood, 2021, 138, 1985-1985.	1.4	0
21	Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 4138-4138.	1.4	0
22	Clinical Characteristics and Outcome of Patients with EZH2- Mutant Myelodysplastic Syndromes. Blood, 2021, 138, 1531-1531.	1.4	2
23	Outcomes of Patients with AML Treated with CPX-351 Based on the 2017 ELN Risk Stratification. Blood, 2021, 138, 1250-1250.	1.4	0
24	Different Treatment Approaches to Blast Phase-Myeloproliferative Neoplasms. Blood, 2021, 138, 3641-3641.	1.4	1
25	Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes. Blood, 2021, 138, 536-536.	1.4	3
26	Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML. Blood, 2021, 138, 1484-1484.	1.4	3
27	Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia. Blood, 2021, 138, 2292-2292.	1.4	0
28	Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia. Blood, 2021, 138, 3658-3658.	1.4	0
29	Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood, 2021, 138, 1984-1984.	1.4	0
30	Moving towards a uniform risk stratification system in CMML - How far are we?. Best Practice and Research in Clinical Haematology, 2020, 33, 101131.	1.7	2
31	Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Advances, 2020, 4, 3435-3442.	5.2	30
32	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research, 2020, 93, 106367.	0.8	15
33	Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Advances, 2020, 4, 530-538.	5.2	60
34	Biology and Pathophysiology of MDS with del(5q). , 2020, , 43-54.		1
35	SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Blood, 2020, 136, 25-26.	1.4	0
36	Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leukemia Research, 2019, 84, 106194.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Impact of the Number of Consolidation Chemotherapy Cycles Prior to Allogeneic Stem Cell Transplant for Adults with Acute Myeloid Leukemia in First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S222.	0.4	0
38	Ring Sideroblast Quantification is Highly Predictive of TP53 Mutation in MDS with Excessive Blasts with Prognostic Implications. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S344-S345.	0.4	0
39	Clinical Significance of MYC Oncoprotein Expression on Survival Outcome in Secondary Acute Myeloid Leukemia (sAML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S205-S206.	0.4	0
40	Can increased immunogenicity in chronic myeloid leukemia improve outcomes?. Expert Review of Hematology, 2019, 12, 225-233.	2.2	2
41	Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. <i>Future Oncology</i> , 2019, 15, 257-269.	2.4	25
42	ASXL1/SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes. <i>Blood</i> , 2019, 134, 2598-2598.	1.4	1
43	Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts. <i>Blood</i> , 2019, 134, 4244-4244.	1.4	2
44	CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3894-3894.	1.4	3
45	Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1368-1368.	1.4	3
46	Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax. <i>Blood</i> , 2019, 134, 1357-1357.	1.4	7
47	Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3382-3382.	1.4	1
48	Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 149-149.	1.4	9
49	Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. <i>Blood</i> , 2019, 134, 4621-4621.	1.4	0
50	RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 2052-2052.	1.4	0
51	Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3895-3895.	1.4	4
52	Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience. <i>Blood</i> , 2018, 132, 4259-4259.	1.4	1
53	Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2741-2741.	1.4	5
54	Mixed phenotype acute leukemia with t(9;22): success with nonacute myeloid leukemia-type intensive induction therapy and stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 435-439.	0.5	2

#	ARTICLE	IF	CITATIONS
55	A Review of Autologous Stem Cell Transplantation in Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 217-226.	2.3	73
56	Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 100.	0.8	9
57	Survival Impact of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive (Ph+) de novo Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S296-S297.	0.4	1
58	Hodgkin Lymphoma Mimicking Osteomyelitis. <i>Case Reports in Oncology</i> , 2017, 10, 542-547.	0.7	3
59	Case of relentless chronic phase of chronic myeloid leukaemia. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215370.	0.5	1
60	Burkitt Lymphoma Presenting as an Intracardiac Mass: Case Report and Review of Literature. <i>American Journal of Case Reports</i> , 2016, 17, 553-558.	0.8	13
61	Coccidioidomycosis with Pericardial Involvement: Case Report and Literature Review. <i>American Journal of Medicine</i> , 2016, 129, e21-e25.	1.5	8
62	Outcome of Immune-Suppressive Therapy (IST) and Hematopoietic Stem Cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center Experience. <i>Blood</i> , 2016, 128, 5081-5081.	1.4	0
63	Cold but not sympathomimetics activates human brown adipose tissue in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10001-10005.	7.1	264